vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $18.6M, roughly 1.0× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -0.8%, a 66.6% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -25.7%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
CTMX vs SCYX — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $18.6M |
| Net Profit | $-154.0K | $12.3M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 56.3% |
| Net Margin | -0.8% | 65.7% |
| Revenue YoY | -25.7% | 1808.5% |
| Net Profit YoY | 97.6% | 376.5% |
| EPS (diluted) | — | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $18.6M | ||
| Q3 25 | — | $334.0K | ||
| Q2 25 | $18.7M | $1.4M | ||
| Q1 25 | $50.9M | $257.0K | ||
| Q4 24 | $38.1M | $977.0K | ||
| Q3 24 | $33.4M | $660.0K | ||
| Q2 24 | $25.1M | $736.0K | ||
| Q1 24 | $41.5M | $1.4M |
| Q4 25 | — | $12.3M | ||
| Q3 25 | — | $-8.6M | ||
| Q2 25 | $-154.0K | $-6.9M | ||
| Q1 25 | $23.5M | $-5.4M | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $-2.8M | ||
| Q2 24 | $-6.5M | $-14.5M | ||
| Q1 24 | $13.8M | $411.0K |
| Q4 25 | — | 56.3% | ||
| Q3 25 | — | -2516.5% | ||
| Q2 25 | -6.9% | -701.0% | ||
| Q1 25 | 44.4% | -3350.2% | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | -1563.6% | ||
| Q2 24 | -33.7% | -1255.0% | ||
| Q1 24 | 28.1% | -692.5% |
| Q4 25 | — | 65.7% | ||
| Q3 25 | — | -2572.2% | ||
| Q2 25 | -0.8% | -504.8% | ||
| Q1 25 | 46.2% | -2097.7% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | -425.5% | ||
| Q2 24 | -26.0% | -1964.4% | ||
| Q1 24 | 33.3% | 29.9% |
| Q4 25 | — | $0.25 | ||
| Q3 25 | — | $-0.17 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $-0.30 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $49.4M |
| Total Assets | $175.1M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | $49.0M | $44.8M | ||
| Q1 25 | $47.6M | $40.6M | ||
| Q4 24 | $38.1M | $59.3M | ||
| Q3 24 | $40.6M | $68.8M | ||
| Q2 24 | $43.2M | $73.0M | ||
| Q1 24 | $36.2M | $80.2M |
| Q4 25 | — | $49.4M | ||
| Q3 25 | — | $36.4M | ||
| Q2 25 | $119.9M | $44.5M | ||
| Q1 25 | $25.0M | $50.5M | ||
| Q4 24 | $-456.0K | $55.1M | ||
| Q3 24 | $-23.5M | $58.5M | ||
| Q2 24 | $-31.2M | $60.4M | ||
| Q1 24 | $-31.7M | $74.1M |
| Q4 25 | — | $59.0M | ||
| Q3 25 | — | $51.1M | ||
| Q2 25 | $175.1M | $60.7M | ||
| Q1 25 | $98.5M | $67.9M | ||
| Q4 24 | $120.5M | $90.6M | ||
| Q3 24 | $139.0M | $99.0M | ||
| Q2 24 | $159.2M | $107.8M | ||
| Q1 24 | $184.7M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $18.4M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $18.4M | ||
| Q3 25 | — | $-8.7M | ||
| Q2 25 | $-15.8M | $-7.5M | ||
| Q1 25 | $-21.0M | $-7.5M | ||
| Q4 24 | $-19.9M | $-24.0M | ||
| Q3 24 | $-20.7M | $765.0K | ||
| Q2 24 | $-19.5M | $-10.9M | ||
| Q1 24 | $-26.0M | $-4.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
